Mandate

Vinge has advised Smart Eye in connection with a capital raising of MSEK 150

March 22, 2024

Vinge has advised Smart Eye Aktiebolag in connection with a directed new issue of shares to Swedish and international investors which provided Smart Eye with SEK 150 million. The subscription price amounted to SEK 91 which was determined through an accelerated bookbuilding procedure arranged by Carnegie.

Vinges team bestod huvudsakligen av Anders Strid, Edin Agic och Hannah Mark.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025